Track topics on Twitter Track topics that are important to you
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
As represented by its name, (Athersys - derived from advanced therapeutic systems), the Company is committed to developing novel therapeutic products that deliver substantial improvements over existing therapies through the application and utilization of its advanced, proprietary technology platforms.
Through internal development and acquisition of key technologies, Athersys has established a unique blend of competencies in areas such as molecular biology, cell biology, genomics, protein biochemistry, medicinal chemistry, and pharmacology. The Company has fully integrated pre-clinical drug discovery and development capabilities, and is focused on advancing a portfolio of therapeutic development programs into the clinic.
3201 Carnegie Avenue
United States of America
Email: firstname.lastname@example.org., email@example.com
Biospectrum All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai [Re...
Athersys Inc. announced public Japanese regenerative medicine company Healios KK as its new MultiStem cell therapy partner in Japan. This comes shortly after Athersys ended its March 2015 MultiStem al...
Edison Investment Research - Pharmaceutical & Healthcare - Athersys: Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has end...
Shares of USA-based biotech firm Athersys rose 21.4% to $1.25 on Friday after it announced a lucrative…
Edison Investment Research - Pharmaceutical & Healthcare - Athersys: Athersys is developing off-the-shelf multipotent adult progenitor cells (MAPCs) to treat a variety of indications, with ischemic st...
Edison Investment Research - Pharmaceutical & Healthcare - Athersys: In its Q215 earnings release, Athersys provided much needed additional data with regard to its Phase II MultiStem trial in ischaemi...
Athersys has granted Healios the exclusive rights to market MultiStem, a stem cell technology designed for ischemic stroke pa -More-
CLEVELAND and TOKYO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) (Tokyo Stock Exchange:4593) and Athersys, Inc. (“Athersys”) (NASDAQ:ATHX) announced today that the companie...
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.As represented by its name, (Ather...
Athersys is a biotechnology company engaged in the research and development of products for the treatment and diagnosis of genetic and immunologic disorders. The company has a core expertise in the f...
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company ...
We have published hundreds of Athersys news stories on BioPortfolio along with dozens of Athersys Clinical Trials and PubMed Articles about Athersys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athersys Companies in our database. You can also find out about relevant Athersys Drugs and Medications on this site too.
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...